FDA extends review period for BioCryst pediatric drug application to December

Published 25/06/2025, 12:06
FDA extends review period for BioCryst pediatric drug application to December

The U.S. Food and Drug Administration has extended its review period for BioCryst Pharmaceuticals’ (NASDAQ:BCRX) new drug application for once-daily ORLADEYO (berotralstat) oral granules intended for pediatric patients with hereditary angioedema aged 2 to 11 years. The company reported Monday that the FDA determined additional final reports and formulation data submitted by BioCryst represented a major amendment to the application, which resulted in a standard three-month extension of the Prescription Drug User Fee Act (PDUFA) goal date.

The new target action date for the FDA’s decision is December 12, 2025. The original review timeline was extended to allow the agency sufficient time to complete a full evaluation of the new information provided.

This information is based on a statement released by BioCryst Pharmaceuticals in a filing with the Securities and Exchange Commission.

In other recent news, BioCryst Pharmaceuticals has reported significant developments regarding its hereditary angioedema (HAE) treatment, ORLADEYO (berotralstat). The company shared data from multiple studies highlighting the long-term efficacy and safety of ORLADEYO across various age groups. Notably, the pediatric APeX-P study showed an 86% reduction in HAE attacks requiring professional care after 12 weeks of treatment. Additionally, BioCryst announced that Colombia’s National Institute of Drug and Food Surveillance has approved ORLADEYO for preventing HAE attacks in patients aged 12 and older, marking its sixth regulatory authorization in Latin America. In Europe, the Netherlands has approved ORLADEYO for reimbursement, expanding its availability across major European countries. Meanwhile, BioCryst has extended its consulting agreement with former Chief Financial Officer Anthony Doyle to ensure continuity in its financial operations. The company remains focused on improving the lives of individuals with rare diseases through its targeted therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.